A transplant recipient is starting maribavir for post-transplant cytomegalovirus infection. Classify each finding by the medication-safety decision it supports.
Matrix
Choose your responses, then check the answer.
Explanation
Valganciclovir or ganciclovir can be antagonized by maribavir; rifampin or St. John wort can reduce maribavir efficacy; digoxin and calcineurin-inhibitor exposure may increase; CMV DNA must be followed for failure or relapse.
Quick answer Separate antiviral antagonism, pharmacokinetic interaction, and virologic surveillance.
Why this is correct Maribavir has clinically important bidirectional interactions and resistance-related failure can occur during or after therapy. Medication reconciliation and CMV DNA monitoring are both essential.
Easy analogy or mental picture Use a closed medication-safety loop: identify the immune or cytotoxic exposure, connect the new findings, interrupt further harm, stabilize the client, and verify the response over time.
Memory hook Exposure, immune effect, organ toxicity, infection risk, immediate action, and serial reassessment.
NCLEX decision rule Choose the action that reduces the most immediate medication-related risk while preserving diagnostic evaluation and authorized treatment.
Why the other choices are wrong Options that continue the exposure, treat only one symptom, or delay reassessment leave the toxic or infectious process active.
References
1DailyMed: LIVTENCITY (maribavir)Antagonism with ganciclovir or valganciclovir, CYP3A inducer effects, monitored interactions, and CMV DNA follow-up
Oncology, transplant, and biologic safety reviewVerify the indication, immune status, infection screen, interacting medicines, current organ findings, authorized action, and measurable follow-up.